These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 16138487)
1. Strategies for reducing the exposure to donor blood. Murphy M Clin Med (Lond); 2005; 5(4):337-40. PubMed ID: 16138487 [No Abstract] [Full Text] [Related]
2. Kill and cure. The hope and reality of virus inactivation. Prowse C Vox Sang; 1994; 67 Suppl 3():191-6. PubMed ID: 7975491 [No Abstract] [Full Text] [Related]
3. Is there a limit to the normality of blood products? Degos L Hematol J; 2000; 1(5):291. PubMed ID: 11920204 [No Abstract] [Full Text] [Related]
4. Bacteria and safety of the blood supply. Kuehnert MJ; Jarvis WR Ann Intern Med; 1998 Jul; 129(2):164-5. PubMed ID: 9669985 [No Abstract] [Full Text] [Related]
5. Safety of the blood supply. Sloand EM; Pitt E; Klein HG JAMA; 1995 Nov; 274(17):1368-73. PubMed ID: 7563562 [No Abstract] [Full Text] [Related]
6. Reducing the residual risk of transfusion-transmitted viruses: mini-pool or single-donation NAT? Roth WK; Seifried E Transfusion; 2001 Jun; 41(6):845-7. PubMed ID: 11399831 [No Abstract] [Full Text] [Related]
7. The role of leukodepletion in the control of transfusion-transmitted disease. Goldman M; Delage G Transfus Med Rev; 1995 Jan; 9(1):9-19. PubMed ID: 7719040 [No Abstract] [Full Text] [Related]
8. [Viral safety measures of plasma for transfusion and applicability in Spain]. Pereira A Med Clin (Barc); 2007 Oct; 129(12):458-68. PubMed ID: 17953912 [No Abstract] [Full Text] [Related]
9. Genomic screening for blood-borne viruses in transfusion settings. Lee HH; Allain JP Vox Sang; 1998; 74 Suppl 2():119-23. PubMed ID: 9704433 [No Abstract] [Full Text] [Related]
10. Approaches to the reduction of viral infectivity in cellular blood components and single donor plasma. Wagner SJ; Friedman LI; Dodd RY Transfus Med Rev; 1991 Jan; 5(1):18-32. PubMed ID: 1802274 [No Abstract] [Full Text] [Related]
11. Current issues in transfusion therapy. 1. Risks of infection. Coffin CM Postgrad Med; 1986 Dec; 80(8):219-24. PubMed ID: 3786281 [TBL] [Abstract][Full Text] [Related]
12. [Current tactics in reducing hazards of virus infection transmission during blood transfusion]. Golosova TV Gematol Transfuziol; 1992 Mar; 37(3):35-7. PubMed ID: 1516800 [No Abstract] [Full Text] [Related]
13. Safety of the blood supply in the United States: opportunities and controversies. AuBuchon JP; Birkmeyer JD; Busch MP Ann Intern Med; 1997 Nov; 127(10):904-9. PubMed ID: 9382369 [TBL] [Abstract][Full Text] [Related]
15. [Transfusion safety and hemosurveillance]. Romeiras MC Acta Med Port; 2000; 13(4):199-202. PubMed ID: 11155487 [TBL] [Abstract][Full Text] [Related]
16. How to limit allogenic blood transfusion in children. Woloszczuk-Gebicka B Paediatr Anaesth; 2005 Nov; 15(11):913-24. PubMed ID: 16238550 [No Abstract] [Full Text] [Related]
17. A method for the production of AHG rich cryoprecipitates & their use in the management of bleeding episodes in haemophilia. Kwa SB; Chen YF Singapore Med J; 1968 Mar; 9(1):12-6. PubMed ID: 5659889 [No Abstract] [Full Text] [Related]
18. [Risks to donor and recipient in blood collection and blood transfusion]. Bergmann H Infusionsther Klin Ernahr; 1977 Apr; 4(2):84-6. PubMed ID: 558163 [TBL] [Abstract][Full Text] [Related]